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Background: Response Evaluation Criteria in Solid Tumors (RECIST) are widely used to assess the effect of
chemotherapy in patients with cancer. We hypothesised that the change in unidimensional tumour size handled as
a continuous variable was more reliable than RECIST in predicting overall survival (OS).
Methods: The prospective Pharmacogenoscan study enrolled consecutive patients with non-small-cell lung cancer
(NSCLC) at any stage seen between 2005 and 2010 at six hospitals in France, given chemotherapy. After exclusion
of patients without RECIST or continuous-scale tumour size data and of those with early death, 464 patients were
left for the survival analyses. Cox models were built to assess relationships between RECIST 1.1 categories or change
in continuous-scale tumour size and OS. The best model was defined as the model minimising the Akaike Information
Criterion (AIC).
Results: OS was 14.2 months (IQR, 7.3-28.9 months). According to RECIST 1.1, 146 (31%) patients had a partial or
complete response, 245 (53%) stable disease, and73 (16%) disease progression. RECIST 1.1 predicted better OS than
continuous-scale tumour in early (<6 months) predicted survival analyses (p = 0.03) but the accuracy of the two
response evaluation methods was similar in late (≥6 months) predicted survival analyses (p = 0.15).
Conclusion: In this large observational study, change in continuous-scale tumour size did not perform better than
RECIST 1.1 in predicting survival of patients given chemotherapy to treat NSCLC.
Trial registration: NCT00222404
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Response Evaluation Criteria in Solid Tumors (RECIST)
was developed in 2000 [1] to assess changes in solid
tumour size in patients given cancer chemotherapy.
RECIST criteria are based on the sum of the maximum
diameters of target lesions seen on imaging studies. This
value is categorised as follows: complete/partial response
(CR/PR), complete disappearance of all targets/greater than
30% decrease; stable disease (SD), change between −30%
and +20%; and progressive disease (PD), greater than 20%* Correspondence: AToffart@chu-grenoble.fr
1Université Grenoble 1 INSERM U 823-Institut A Bonniot-Université J Fourier,
Rond-point de la Chantourne, 38706 La Tronche Cedex, France
2Thoracic Oncology Unit, Centre Hospitalier Universitaire A Michallon, 2-BP
217, 38043 Grenoble cedex, France
Full list of author information is available at the end of the article
© 2014 Toffart et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.increase. The initial RECIST guidelines (RECIST 1.0) were
revised in 2009 (RECIST 1.1) [2] to improve the definitions
of the target lesions. RECIST categories have gradually su-
perseded the World Health Organisation (WHO) criteria
for chemotherapy effects, which use bidimensional tumour
measurements to define CR, PR, SD, and PD [3]. RECIST
categories were found to be associated with survival [4,5].
It has been suggested that a patient with 15% tumour
shrinkage may have a better survival than a patient with
15% tumour growth, although both patients fall in the
stable-disease category according to RECIST criteria.
Therefore, the change in tumour size from baseline handled
as a continuous variable, which differentiates such patients,
might help to assess antitumor activity and to predict sur-
vival [6]. Data from phase I [7], II [8], and III [9,10] clinical
trials indicate that unidimensional continuous-scale tumourThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
537 Full analysis set patients 
10 excluded 
         4 patients denied consent 
         6 met exclusion criteria 
540 intent-to-treat patients  
550 patients included between 
July 2005 and August 2010
3 deaths before onset of treatment 
4: chemotherapy interruption for toxicity 
without tumour size evaluation 
2: lost to follow-up just after chemotherapy 
531 patients studied 
Tumor measurement missing for 67 patients: 
- 31: imaging studies not available  
- 5: tumor size not measurable (pleural or 
pericardial effusion in 4 and lung abscess in 1) 
- 25: early death before evaluation 
- 6: early progression before the end of the second 
chemotherapy cycle
RECIST evaluable 
for 464 patients 
Figure 1 Flow chart.
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http://www.biomedcentral.com/1471-2407/14/989size (UCSTS) measurement is feasible and probably useful
for assessing treatment effectiveness, particularly when the
number of patients is small. However, UCSTS measurement
may be difficult to perform. Further new lesions cannot
be quantified numerically, and consequently are gener-
ally classified as PD or ignored.
Pharmacogenoscan is a large translational study aimed
at associating the molecular profiles of tumour and blood
samples with the response to first-line chemotherapy in
patients with non-small-cell lung cancer (NSCLC). The
primary objective of the study reported here was to com-
pare the performance of UCSTS changes and RECIST
1.1 categories in predicting overall survival (OS) in the
Pharmacogenoscan cohort.
Methods
Patients and study design
The Pharmacogenoscan study is a prospective study con-
ducted in six hospitals in the Rhône-Alpes-Auvergne region
of France to identify biological and histological factors asso-
ciated with outcomes of patients with NSCLC. The study
was approved by the ethics committee of the Grenoble
University Hospital (NCT00222404), and all patients gave
written informed consent before study inclusion.
Consecutive patientswith chemotherapy-naive NSCLC
at any stage [11,12] seen between July 2005 and August
2010 and having an ECOG-performance status (PS) [13]
of 0 to 2 were included if they received platinum-based
doublet chemotherapy as either neo-adjuvant or first-
line treatment for metastatic or recurrent disease. All
clinical data were recorded prospectively. Missing data
were retrieved by one of us (ACT) before database lock.
As shown in the patient flow chart (Figure 1), we in-
cluded 550 patients. We excluded 67 patients because of
an inability to evaluate UCSTS changes or because of
early death or disease progression. Landmark analysis
[14,15] was performed in these patients with a time
point taken at 6 weeks. Finally, RECIST categories were
available and studied for 464 patients.
Tumour size evaluation
Baseline imaging was performed 20 days (25%-75% inter-
quartile range (IQR), 12–31 days) before chemotherapy
initiation, and the first follow-up evaluation occurred after
two or three chemotherapy cycles (median, 42 days; IQR,
35–47 days) as decided by the investigator. Targets were
measured on computed tomography (CT) images and
reassessed for the purpose of the study by at least one
physician specialised in thoracic oncology (ACT, DMS,
PM, MP, PJS, PR, or PC). RECIST 1.1 response categories
were determined [2]. For patients included before 2009,
RECIST 1.0 categories were converted into RECIST 1.1
categories [16]. A systematic blind review of tumour re-
sponse according to RECIST criteria was performed in arandom sample of patients included by independent in-
vestigators belonging to different centres. The change in
UCSTS over time was computed as follows: (UCSTS at
first follow-up evaluation –UCSTS at baseline)/UCSTS at
baseline. For the patients with at least one new lesion, we
assigned a 100% increase in UCSTS measurement.
Statistical analysis
Distributions of continuous variables were summarized by
median (IQR) and of categorical variables by counts
(percentages). Patients who were lost to follow-up by 1
December 2012 were considered censored. Follow-up
duration was defined as the time from the first chemo-
therapy dose to last follow-up, and OS as the time from
the first chemotherapy dose to death.
Kaplan-Meier curves of OS were plotted and compared
between groups using the log-rank test. Univariate analyses
were used to identify factors associated with OS. Variables
associated with P-values lower than 0.20 by univariate ana-
lysis and those known to affect OSwere proposed to multi-
variate Cox models using a stepwise procedure. Variables
associated with p < 0.05 in the multivariate context were
kept in the models. The proportional hazard assumption
was checked using martingale residuals. For this as-
sumption to be plausible, we separately analysed early
(<6 months) and late (≥6 months) deaths, using Cox
Toffart et al. BMC Cancer 2014, 14:989 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/989models. Analyses were stratified for the ECOG-PS and
the hospital. Hazard ratios (HRs) with their 95% confi-
dence intervals (95% CIs) and p values were computed.
We compared the non-nested RECIST and UCSTS models
based on the Akaike Information Criterion (AIC).The AIC
is maximum likelihood function penalised by the number
of variables included in the model. It offers a relative esti-
mate of the information lost when a given model is used to
represent the process that generates the data. It defines the
best model as the one with the lowest AIC value [17]. To
evaluate the significance of the AICs’ difference, weTable 1 Univariate analysis (log rank test)
Patient characteristics Total (%) n = 464 Deceased
Gender
Male 353 (76) 292 (83)
Female 111 (24) 100 (90)
Age (by quartile)
< 54 years 112 (24) 96 (86)
54-60 years 112 (24) 95 (85)
60-67 years 117 (25) 96 (82)
≥ 67 years 123 (27) 105 (85)
Performance status
0 183 (39) 149 (81)
1 261 (56) 224 (86)
2 20 (4) 19 (95)
Charlson comorbidity index [18]
0 378 (81) 321 (85)
≥ 1 86 (19) 71 (83)
Histology
Adenocarcinoma 279 (60) 247 (89)
Squamous cell carcinoma 112 (24) 79 (71)
Large cell carcinoma 73 (16) 66 (90)
Cancer spread
Localised (II IIIA) 83 (18) 49 (59)
Advanced (IIIB) 97 (21) 75 (87)
Metastatic (IV) 284 (61) 268 (94)
Platinum-based doublet
Platinum-gemcitabine 179 (39) 150 (84)
Platinum-vinorelbine 77 (17) 64 (82)
Platinum-docetaxel 74 (16) 64 (86)
Platinum-paclitaxel 70 (15) 61 (87)
Platinum-pemetrexed 64 (14) 54 (84)
Tumour response
Complete/partial response 146 (31) 108 (74)
Stable disease 245 (53) 213 (87)
Progressive disease 73 (16) 71 (97)
IQR: interquartile range.calculated a chi-square (difference between -2log likelihood
of both models) at a degree of freedom (difference between
degrees of freedom of both models). Thus we obtained a
P-value. All statistical analyses were performed using SAS
9.3 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Figure 1 is the patient flow chart. Table 1 lists the main
patient characteristics. The majority of patients had in-





















































Figure 2 Response according to percentage change in unidimensional continuous-scale tumour size (waterfall plot).
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http://www.biomedcentral.com/1471-2407/14/989(96%). Various platinum-based chemotherapy doublets
were used and 21 (5%) patients received a chemotherapy
triplet including bevacizumab. Median follow-up dur-
ation was 13.7(IQR 7.2-28.1) months and median OS
14.2 (IQR, 7.3-28.9) months.
Median OS was 14.7 (IQR, 8.0-25.8) months in patients
with no available CT scans and 15.8 (IQR, 10.2-31.6)
months in those with non-measurable tumours.Tumour response
According to RECIST, 146 (31%) patients had a CR or PR,
245 (53%) SD, and 146 (31%) PD. The systematic review of
the tumour response was performed for the first 64 (14%)
patients and showed agreement with the initial evaluation
in 60 (94%). The discrepancies were resolved by discussion.
Patients with measurable changes in tumour size had
changes ranging from a 100% decrease to a 100% increase,
with 347 (75%) showing at least some decrease according
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Figure 3 1-year survival in patients with metastatic disease accordingFigure 3 shows 1-year survival in patients with metastatic
disease according to the change in UCSTS. In this group,
1-year mortality was about 50% for UCSTS changes be-
tween −100% and +20% (CR + PR + SD RECIST categories)
and greater than 80% for UCSTS increases greater than
20% (PD RECIST category). In non metastatic tumours,
predicted survival was related linearly with the logit of per-
centage of response without clear cut-off.
Association between tumour response and overall
survival (OS)
By univariate analysis (Table 1), ECOG-PS, histologic
cancer type, and cancer spread (TNM classification) were
significantly associated with OS. Response according to
RECIST was associated with OS (p < 10−4, Figure 4).
Tables 2 and 3 show the results of the Cox models for
the first 6 months and subsequent period, respectively. The
analysis was routinely adjusted on histology and cancer
spread. Sex and chemotherapy doublet were proposed to
the model but not kept at the final step. The analysis was27 n=23 n=9 n=7 n=40
ges in tumour size
to change in unidimensional continuous-scale tumour size.
Figure 4 Kaplan-Meier survival estimate according to RECIST.
Table 3 Akaike Information Criterion (AIC) values for the
Cox models, Beyond the first 6 months of follow-up (370
patients)
Model HR (95% CI) p value AIC*
RECIST Partial response 1 1835.264
Stable disease 1.19 (0.90-1.58) 0.22
Progressive disease 3.12 (1.89-5.14) <10−4
UCSTS per 10% difference 1.07 (1.03-1.11) <10−4 1835.312
The analysis was routinely adjusted on histology and cancer spread. Sex and
chemotherapy doublet were proposed to the model but not kept at the final
step. The analysis was stratified on ECOG-PS and hospital.
*In the model with RECIST, −2log likelihood = 1823.264 with 6 degrees
of freedom.In the model with UCSTS, −2log likelihood = 1825.312 with 5
degrees of freedom.
p = 0.15.
HR, hazard ratio; 95% CI, 95% confidence interval; RECIST, Response Evaluation
Criteria in Solid Tumors; UCSTS, unidimensional continuous-scale tumour size.
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hospital. Accuracies as estimated by the AIC were better
for RECIST 1.1 (p = 0.03) than for UCSTS, even after ad-
justment on confounders for early survival. However, no
difference in accuracy was found between RECIST 1.1 and
UCSTS for late survival (p = 0.15).
Discussion
In our study, tumour response to chemotherapy evalu-
ated based on either RECIST or UCSTS was strongly as-
sociated with OS. UCSTS did not perform better than
RECIST in predicting OS.We studied a large cohort of
patients with NSCLC selected only based on ECOG-PS.
Our population is representative of the NSCLC patients
seen in daily practice. In particular, most patients had
adenocarcinoma and 60% had metastatic disease.
RECIST 1.1 was superior over UCSTS in predicting
early survival, probably due to the weight of poor prog-
nosis among patients with PD. For predicting late
survival, the two methods were similarly accurate. WeTable 2 Akaike Information Criterion (AIC) values for the
Cox models, First 6 months of follow-up (464 patients)
Model HR (95% CI) p value AIC*
RECIST Partial response 1 575.762
Stable disease 2.29 (1.06-4.94) 0.03
Progressive disease 18.48 (8.41-40.59) <10−4
UCSTS per 10% difference 1.21 (1.16-1.26) <10−4 578.585
The analysis was routinely adjusted on histology and cancer spread. Sex and
chemotherapy doublet were proposed to the model but not kept at the final
step. The analysis was stratified on ECOG-PS and hospital.
*In the model with RECIST, −2log likelihood = 563.762 with 6 degrees
of freedom. In the model with UCSTS changes, −2log likelihood = 568.585 with
5 degrees of freedom.
p = 0.03.
HR, hazard ratio; 95% CI, 95% confidence interval; RECIST, Response Evaluation
Criteria in Solid Tumors; UCSTS, unidimensional continuous-scale tumour size.are aware of a single previous study [19] of UCSTS
versus WHO criteria for predicting survival. The pa-
tients had colorectal cancer and were given conventional
chemotherapy. UCSTS did not perform better than
WHO criteria with the three categories CR/PR, SD, and
PD. One possible explanation is the variability in CT
measurements of tumour size. In a study of 33 patients
with NSCLC, the interobserver relative measurement
change in unidimensional tumour size measurements
varied from 0% to 194% [20]. In patients with a variety
of thoracic and abdominal tumours, the results obtained
by a single observer compared with multiple observers
differed by more than 10% for 83% of lesions [21]. Fi-
nally, among patients with NSCLC, measurements on
two CT scans obtained within less than 15 minutes often
showed differences exceeding 1 or 2 mm [22].Thus,
small changes in tumour size should be interpreted with
caution. When using the WHO criteria,tumour meas-
urement errors can be expected to produce objective re-
sponse rates ranging from of 5% to 10% [23].Tumour
response evaluation using RECIST appeared more repro-
ducible. In our study, the review of results by a panel of
experts found errorsin only 6% of patients. Andoh et al.
[24] assessed the quality of radiology reports requiring
RECIST and found that the combination of distributed
educational materials and audit and feedback interven-
tions improved radiology report quality by reducing the
number of studies with errors from 30% to 22%.
Response rates (responders versus non-responders) do
not include SD in the response category. Response is a
common endpoint in phase III studies but performs
poorly in predicting survival [25]. Patients can experi-
ence clinical benefits from treatment without a signifi-
cant change in tumour size. Our results in the subgroup
with metastatic disease suggest that a 20% increase in
UCSTS (PD) may be a satisfactory cut-off for separating
two prognostic groups. A study of patients with NSCLC
[26] is consistent with this assumption: the 8-week rate
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performed better in predicting survival than did the
8-week rate of CR/PR. Recently, Mandrekar et al. [27]
published the results from 13 trials including patients
with metastatic cancer. They confirmed the utility of the
RECIST-based response metrics. No alternative cut-offs
or alternative categorical metrics appeared better than
the RECIST standards.
One limitation of our study is the exclusion of 13% of the
patients from the analysis. Most of these patients had early
progression or death and were excluded to meet the condi-
tions required for a landmark analysis [14,15], i.e., to avoid
bias in favour of responders. In our study we assigned a
100% increase in the UCSTS measurement for new lesions.
They were excluded from the survival analysis, but finally,
only 3% of patients had PD. We acknowledge that this way
of expressing data may be over-simplistic. Furthermore, as
the time of response evaluation was decided by each investi-
gator (after 2 or 3 cycles of chemotherapy) the assessments
were not performed within a 2-week window. Various
chemotherapy doublets were used, and most patients (69%)
received at least one subsequent line of chemotherapy,
which may have attenuated the association between tumour
shrinkage achieved with first-line chemotherapy and OS.
Conclusion
In this large observational study of NSCLC patients
given chemotherapy, UCSTS did not better perform
than RECIST in predicting survival. In addition, our re-
sults suggest that distinguishing between PR and SD
may be unhelpful for predicting survival of patients with
metastatic disease. RECIST is easier to assess than
UCSTS, which may deserve more specific assessment for
trials with targeted therapies.
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